Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity

Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity

Abstract The prognosis for women with ovarian cancer (OC) is particularly poor if resistance to platinum compounds, the mainstay of standard-of-care therapy, develops. Inhibitors of the Nudix hydrolase MuT Homolog 1 (MTH1) have previously been shown to arrest cancer cells in mitosis, increase 8-oxo-...

Full description

Saved in:
Bibliographic Details
Main Authors: Rachel M. Hurley, Jill M. Wagner, Arun Kanakkanthara, Annapoorna Venkatachalam, Aaron M. Deisinger, Cristina Correia, Paula A. Schneider, Kevin L. Peterson, Elaine P. Macon, Ethan P. Heinzen, Kumar Sanjiv, Xiaonan Hou, Marc A. Becker, Matthew J. Maurer, Melissa C. Larson, Elizabeth M. Swisher, Hu Li, Ann L. Oberg, S. John Weroha, Ulrika Warpman Berglund, Thomas Helleday, Scott H. Kaufmann, Andrea E. Wahner Hendrickson
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Experimental Hematology & Oncology
Subjects:
MTH1 inhibitors
Ovarian cancer
Platinum resistance
PDX models
Online Access:https://doi.org/10.1186/s40164-025-00681-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40164-025-00681-0

Similar Items